###### Summary

What is already known about this topic?
=======================================

Routine human papillomavirus (HPV) vaccination is recommended for children aged 11 or 12 years to prevent HPV and associated cancers.

What is added by this report?
=============================

Geographic disparities in HPV vaccine coverage exist in the Mississippi Delta Regional Authority (DRA) counties and other counties in Delta states, compared with states outside the Delta region.

What are the implications for public health practice?
=====================================================

Efforts to improve coverage are needed, particularly in the DRA region and other counties in Delta states. Providing parents and guardians with information and strong, compelling recommendations can improve HPV vaccination coverage.

Introduction
============

The Delta Regional Authority (DRA) was established in 2000 by the US Congress to support economic development and improve living standards for approximately 10 million residents in 252 designated counties and parishes in 8 Mississippi Delta states: Alabama, Arkansas, Illinois, Kentucky, Louisiana, Mississippi, Missouri, and Tennessee ([Figure](#F1){ref-type="fig"}) ([@R1]). Counties in the DRA region are significantly disadvantaged, and 43.3% are classified as in persistent poverty, versus 11.2% in the nation as a whole ([@R2]).
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Residents of the Delta region have a poorer health status than do other US residents ([@R3]). Residents in the DRA region are more likely than other US residents to have a high body mass index, high blood pressure, diabetes, and are more likely to smoke and die of cancer ([@R4],[@R5]). Although DRA counties are uniquely disadvantaged, they are located in Mississippi Delta states where other counties have similar demographic factors. Despite similarities, compared with counties in these states but outside the DRA region, DRA counties have substantially worse health indicators, such as those associated with social determinants of health and cardiovascular disease morbidity and mortality ([@R6],[@R7]).

A 2005 county-level analysis indicated that DRA counties had a median cancer mortality rate that was approximately 8.5% higher than in counties in Delta states outside the DRA region ([@R8]). Overall, residents inside DRA areas have a substantially higher incidence of human papilloma virus (HPV)-associated cancers than US residents overall ([@R9]), particularly cervical cancer [@R10], as well as a higher incidence of sexually transmitted infections other than HPV ([@R11]).

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of children aged 11 or 12 years with HPV vaccine to prevent HPV-associated cancers ([@R12],[@R13]). Despite this recommendation, HPV vaccination coverage has remained low nationally relative to other recommended vaccines ([@R14]). Coverage of HPV vaccine in DRA areas has not been documented.

The objective of this analysis was to 1) better understand HPV vaccination coverage among adolescents in DRA areas and how it compares to the rest of the nation, 2) examine the association of sociodemographic and health care-related factors with HPV vaccination, and 3) examine HPV vaccination intentions and reasons for hesitancy among parents of unvaccinated adolescents.

Methods
=======

The National Immunization Survey-Teen (NIS-Teen) is a random-digit--dialed telephone survey of parents or guardians of adolescents aged 13 to 17 years. NIS-Teen also includes a survey mailed to all vaccination providers identified by the parent and those who consented to contact for vaccination history ([@R15]). NIS-Teen uses a national probability sample of households in the United States, which includes all 50 states, the District of Columbia, and selected local areas.

We analyzed NIS-Teen data from 2015, 2016, and 2017, collected from households by way of landlines and cellular telephones ([@R16],[@R17]). Provider-reported vaccination records were used to determine all HPV vaccination coverage estimates among adolescents. In this analysis, adolescents without adequate provider data were excluded; NIS-Teen methodology assigns provider phase weights to control for both provider nonresponse and for adolescents without adequate provider data for other reasons ([@R18],[@R19]). Details of the NIS-Teen methodology, including how multiple survey years of vaccination data are combined to produce a synthesized immunization history and a description of the weighting procedure, have been published ([@R16],[@R17]). The 2015--2017 NIS-Teen was approved by the National Center for Health Statistics Research Ethics Review Board, and the NORC (National Opinion Research Center) at the University of Chicago Institutional Review Board.

We included data from 63,299 adolescents, aged 13 to 17 years, in 2015--2017 NIS-Teen. Inclusion criteria required that adolescents have adequate provider data (ie, vaccination history documentation from provider reports) to determine whether they were up-to-date with vaccinations. The Council of American Survey Research Organizations (CASRO) landline response rates were 56.4% for 2015, 55.5% for 2016, and 51.5% for 2017. CASRO response rates for the cell phone sample were 29.8% for 2015, 29.5% for 2016, and 23.5% for 2017 ([@R20]). The annual number of adolescents with completed household interviews and adequate provider data in the sample was 21,875 (49.8%) for 2015; 20,475 (48.8%) for 2016; and 20,949 (48.1%) for 2017 ([@R20]).

We categorized our study population into 3 geographic areas: inside DRA areas (n = 2,317), Delta areas outside the DRA (counties and parishes outside the DRA in the 8 Mississippi Delta states, n = 6,028), and non-Delta states (the District of Columbia and the remaining United States that are outside the Mississippi Delta, n = 54,954). We examined a dichotomous outcome of HPV vaccine initiation (≥1 HPV vaccine dose or not vaccinated). We compared HPV vaccination initiation coverage estimates in the DRA region to coverage estimates in the other 2 geographic areas. We also estimated HPV vaccination initiation coverage for selected covariates, including demographic characteristics (sex, age, and race/ethnicity of adolescent mother's education, marital status, income-to-poverty ratio \[IPR, total family income divided by the federal poverty level\], and residence), health insurance, and access to care variables for adolescents (preventive care visit at 11--12 years, received provider recommendation for HPV, total number of vaccination providers, number of physician contacts in the past year, and type of facility providing the vaccinations). Among parents with adolescents unvaccinated for HPV, we examined intent to vaccinate their adolescents in the next year by asking parents, "How likely is it that \[TEEN\] will receive HPV shots in the next 12 months?" Response options included "very likely," "somewhat likely," "not sure or don't know," "not too likely," and "not likely at all." Parents who indicated the last 3 responses were asked, "What is the main reason \[TEEN\] will not receive HPV shots in the next 12 months?" This open-ended question allowed parents to indicate multiple reasons, and we identified the top 5 reasons from verbatim responses.

We conducted statistical analyses by using SAS-callable SUDAAN release 11.0.1 (RTI International) to account for the complex sampling design of the NIS-Teen data. Point estimates and their 95% confidence intervals (CIs) were weighted to be representative of the areas from which the households were sampled. We used bivariate analyses to describe the distribution across selected sociodemographic characteristics. We used *t* tests to identify significant differences (*P* \< .05) in the proportion of categories between the DRA region and Delta areas outside the DRA authority and non-Delta states. We also conducted a multivariable logistic regression analysis to produce adjusted prevalence ratios (APRs) and 95% CIs by using a standard statement in SUDAAN procedures to produce such estimates (model-adjusted risk). We used χ^2^ tests to identify covariates that were associated with HPV vaccination initiation in each of the 3 geographic areas.

Results
=======

Demographic characteristics differed substantially between adolescents living inside DRA areas and adolescents living in Delta areas outside the DRA or in non-Delta states ([Table 1](#T1){ref-type="table"}). We found a significantly higher proportion of non-Hispanic black adolescents, adolescents living in rural areas, and adolescents living in a household with an IPR below 133% in the DRA region. A significantly smaller proportion of adolescents inside the DRA region had a mother who had graduated from college or was married, and a higher percentage had mothers aged 34 or younger. Adolescents living in the DRA region also differed significantly in health care access and use, and they were more likely to be enrolled in Medicaid, to have had 4 or more physician contacts in the previous year, to have 2 or 3 vaccination providers, to have received all of their vaccinations in public facilities or a mix of facilities, and to be less likely to report receiving a provider recommendation for the HPV vaccination.

###### Characteristics of Adolescents Aged 13--17 Years by Geographic Area, National Immunization Survey--Teen, United States, 2015--2017

  Characteristic                                                All Surveyed Adolescents in the United States   Mississippi Delta States                            Non-Delta States                                                                                            
  ------------------------------------------------------------- ----------------------------------------------- --------------------------------------------------- ------------------ ------------------- ------- --------------------------------------------------- -------- ---------------------------------------------------
  **Overall**                                                   63,299                                          100.0 (---)                                         2,317              3.0 (2.8--3.1)      6,028   9.9 (9.7--10.1)                                     54,954   87.1 (86.9--87.3)
  **Interview year**                                            63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  2015                                                          21,875                                          33.3 (32.9--33.8)                                   819                34.9 (32.9--37.0)   2,060   33.2 (32.3--34.1)                                   18,996   33.3 (32.8--33.8)
  2016                                                          20,475                                          33.3 (32.9--33.8)                                   771                33.8 (31.8--35.9)   1,907   33.1 (32.2--34.1)                                   17,797   33.3 (32.9--33.8)
  2017                                                          20,949                                          33.3 (32.9--33.8)[a](#T1FN1){ref-type="table-fn"}   727                31.3 (29.2--33.3)   2,061   33.7 (32.7--34.6)                                   18,161   33.4 (32.9--33.9)[a](#T1FN1){ref-type="table-fn"}
  **Sex**                                                       63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  Male                                                          33,285                                          51.1 (50.3--51.8)                                   1,258              51.9 (49.3--54.5)   3,142   50.8 (49.2--52.4)                                   28,885   51.1 (50.2--51.9)
  Female                                                        30,014                                          48.9 (48.2--49.7)                                   1,059              48.1 (45.5--50.7)   2,886   49.2 (47.6--50.8)                                   26,069   48.9 (48.1--49.8)
  **Age of adolescent at interview, y**                         63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  13                                                            12,968                                          19.8 (19.2--20.3)                                   498                21.6 (19.6--23.8)   1,228   19.9 (18.6--21.2)                                   11,242   19.7 (19.0--20.3)
  14                                                            13,252                                          19.9 (19.3--20.5)                                   453                19.5 (17.5--21.7)   1,206   19.1 (17.9--20.4)                                   11,593   20.0 (19.3--20.7)
  15                                                            12,770                                          21.0 (20.4--21.6)                                   474                20.9 (18.9--23.1)   1,251   20.6 (19.4--21.9)                                   11,045   21.0 (20.4--21.7)
  16                                                            12,811                                          20.5 (19.9--21.1)[a](#T1FN1){ref-type="table-fn"}   457                18.2 (16.4--20.2)   1,270   21.4 (20.1--22.7)[a](#T1FN1){ref-type="table-fn"}   11,084   20.5 (19.8--21.1)[a](#T1FN1){ref-type="table-fn"}
  17                                                            11,498                                          18.9 (18.3--19.4)                                   435                19.7 (17.7--21.9)   1,073   19.0 (17.7--20.3)                                   9,990    18.8 (18.2--19.5)
  **Adolescent's race/ethnicity**                               63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  Non-Hispanic white                                            38,728                                          52.9 (52.1--53.6)                                   1,322              51.0 (48.4--53.5)   3,959   63.5 (61.9--65.0)[a](#T1FN1){ref-type="table-fn"}   33,447   51.7 (50.9--52.5)
  Non-Hispanic black                                            5,961                                           13.9 (13.4--14.4)[b](#T1FN2){ref-type="table-fn"}   700                38.2 (35.6--40.8)   743     14.9 (13.7--16.1)[b](#T1FN2){ref-type="table-fn"}   4,518    12.9 (12.4--13.5)[b](#T1FN2){ref-type="table-fn"}
  Hispanic                                                      11,715                                          23.2 (22.5--23.9)[a](#T1FN1){ref-type="table-fn"}   148                4.8 (4.0--5.9)      834     13.3 (12.3--14.4)[a](#T1FN1){ref-type="table-fn"}   10,733   25.0 (24.2--25.8)[a](#T1FN1){ref-type="table-fn"}
  Other                                                         6,895                                           10.1 (9.6--10.5)[a](#T1FN1){ref-type="table-fn"}    147                6.0 (5.0--7.3)      492     8.4 (7.5--9.3)[a](#T1FN1){ref-type="table-fn"}      6,256    10.4 (9.9--10.9)[a](#T1FN1){ref-type="table-fn"}
  **Mother's education**                                        63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  \<High school graduate                                        7,725                                           13.3 (12.8--13.9)                                   335                12.0 (10.5--13.6)   830     10.8 (9.9--11.7)                                    6,560    13.7 (13.0--14.3)[a](#T1FN1){ref-type="table-fn"}
  High school graduate                                          10,020                                          22.5 (21.8--23.2)[b](#T1FN2){ref-type="table-fn"}   497                28.9 (26.5--31.5)   1,070   23.6 (22.1--25.1)[b](#T1FN2){ref-type="table-fn"}   8,453    22.1 (21.4--22.9)[b](#T1FN2){ref-type="table-fn"}
  \>High school graduate, some college                          16,311                                          24.9 (24.2--25.5)[b](#T1FN2){ref-type="table-fn"}   694                30.8 (28.5--33.2)   1,647   26.9 (25.5--28.3)[b](#T1FN2){ref-type="table-fn"}   13,970   24.4 (23.7--25.1)[b](#T1FN2){ref-type="table-fn"}
  College graduate                                              29,243                                          39.3 (38.6--40.0)[a](#T1FN1){ref-type="table-fn"}   791                28.3 (26.2--30.5)   2,481   38.8 (37.2--40.3)[a](#T1FN1){ref-type="table-fn"}   25,971   39.8 (39.0--40.5)[a](#T1FN1){ref-type="table-fn"}
  **Mother's marital status**                                   59,126                                          100.0 (---)                                         2,136              100.0 (---)         5,617   100.0 (---)                                         51,373   100.0 (---)
  Married                                                       44,381                                          67.7 (66.9--68.4)[a](#T1FN1){ref-type="table-fn"}   1,348              51.9 (49.1--54.6)   4,050   65.5 (63.8--67.1)[a](#T1FN1){ref-type="table-fn"}   38,983   68.4 (67.6--69.3)[a](#T1FN1){ref-type="table-fn"}
  Divorced, widowed, or separated                               10,729                                          23.3 (22.6--24.0)[b](#T1FN2){ref-type="table-fn"}   511                30.2 (27.6--32.8)   1,120   24.4 (23.0--26.0)[b](#T1FN2){ref-type="table-fn"}   9,098    22.9 (22.2--23.7)[b](#T1FN2){ref-type="table-fn"}
  Never married                                                 4,016                                           9.1 (8.6--9.5)[b](#T1FN2){ref-type="table-fn"}      277                18.0 (15.8--20.4)   447     10.1 (9.1--11.2)[b](#T1FN2){ref-type="table-fn"}    3,292    8.6 (8.1--9.1)[b](#T1FN2){ref-type="table-fn"}
  **Mother's age, y**                                           63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  ≤34                                                           5,151                                           8.8 (8.4--9.2)[b](#T1FN2){ref-type="table-fn"}      303                14.5 (12.7--16.4)   575     9.6 (8.7--10.6)[b](#T1FN2){ref-type="table-fn"}     4,273    8.5 (8.0--9.0)[b](#T1FN2){ref-type="table-fn"}
  35--44                                                        25,998                                          43.7 (42.9--44.4)[b](#T1FN2){ref-type="table-fn"}   1,072              49.0 (46.4--51.5)   2,688   46.2 (44.6--47.8)                                   22,238   43.2 (42.4--44.0)[b](#T1FN2){ref-type="table-fn"}
  ≥45                                                           32,150                                          47.5 (46.8--48.3)[a](#T1FN1){ref-type="table-fn"}   942                36.6 (34.2--39.1)   2,765   44.2 (42.6--45.8)[a](#T1FN1){ref-type="table-fn"}   28,443   48.3 (47.5--49.1)[a](#T1FN1){ref-type="table-fn"}
  **Adolescent had preventive care visit at age 11 or 12**      62,875                                          100.0 (---)                                         2,299              100.0 (---)         6,000   100.0 (---)                                         54,576   100.0 (---)
  Yes                                                           57,452                                          90.9 (90.4--91.3)                                   2,053              89.7 (88.1--91.2)   5,476   90.7 (89.7--91.6)                                   49,923   91.0 (90.4--91.4)
  No                                                            5,423                                           9.1 (8.7--9.6)                                      246                10.3 (8.8--11.9)    524     9.3 (8.4--10.3)                                     4,653    9.0 (8.6--9.6)
  **Income-to-poverty ratio**                                   63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  \<133%                                                        16,687                                          32.0 (31.3--32.8)[b](#T1FN2){ref-type="table-fn"}   869                42.6 (40.0--45.2)   1,837   32.8 (31.3--34.4)[b](#T1FN2){ref-type="table-fn"}   13,981   31.6 (30.8--32.4)[b](#T1FN2){ref-type="table-fn"}
  133% to \<322%                                                17,243                                          28.1 (27.4--28.7)                                   665                30.4 (28.0--32.9)   1,754   30.9 (29.4--32.4)                                   14,824   27.7 (26.9--28.4)[b](#T1FN2){ref-type="table-fn"}
  322% to \<503%                                                13,132                                          18.2 (17.7--18.7)[a](#T1FN1){ref-type="table-fn"}   387                14.0 (12.5--15.8)   1,183   18.2 (17.0--19.4)[a](#T1FN1){ref-type="table-fn"}   11,562   18.3 (17.7--18.9)[a](#T1FN1){ref-type="table-fn"}
  ≥503%                                                         16,237                                          21.7 (21.1--22.3)[a](#T1FN1){ref-type="table-fn"}   396                13.0 (11.6--14.6)   1,254   18.1 (17.0--19.3)[a](#T1FN1){ref-type="table-fn"}   14,587   22.4 (21.8--23.1)[a](#T1FN1){ref-type="table-fn"}
  **Health insurance status[c](#T1FN3){ref-type="table-fn"}**   63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  Private only                                                  36,269                                          51.6 (50.8--52.3)[a](#T1FN1){ref-type="table-fn"}   1,014              37.9 (35.5--40.3)   3,302   52.8 (51.2--54.4)[a](#T1FN1){ref-type="table-fn"}   31,953   51.9 (51.1--52.7)[a](#T1FN1){ref-type="table-fn"}
  Any Medicaid                                                  19,717                                          37.1 (36.3--37.8)[b](#T1FN2){ref-type="table-fn"}   1,053              51.8 (49.3--54.4)   2,169   38.5 (36.9--40.0)[b](#T1FN2){ref-type="table-fn"}   16,495   36.4 (35.6--37.2)[b](#T1FN2){ref-type="table-fn"}
  Other[d](#T1FN4){ref-type="table-fn"}                         4,885                                           7.1 (6.7--7.4)                                      164                6.8 (5.6--8.2)      359     4.9 (4.3--5.5)[b](#T1FN2){ref-type="table-fn"}      4,362    7.3 (7.0--7.7)
  Uninsured                                                     2,428                                           4.3 (4.0--4.6)                                      86                 3.5 (2.7--4.6)      198     3.9 (3.2--4.6)                                      2,144    4.4 (4.0--4.7)
  **Provider recommended HPV vaccination**                      57,740                                          100.0 (---)                                         2,071              100.0 (---)         5,519   100.0 (---)                                         50,150   100.0 (---)
  Yes                                                           42,603                                          71.7 (71.0--72.4)[a](#T1FN1){ref-type="table-fn"}   1,311              63.5 (60.8--66.0)   3,765   68.4 (66.8--69.9)[a](#T1FN1){ref-type="table-fn"}   37,527   72.4 (71.6--73.2)[a](#T1FN1){ref-type="table-fn"}
  No                                                            15,137                                          28.3 (27.6--29.0)[b](#T1FN2){ref-type="table-fn"}   760                36.5 (34.0--39.2)   1,754   31.6 (30.1--33.2)[b](#T1FN2){ref-type="table-fn"}   12,623   27.6 (26.8--28.4)[b](#T1FN2){ref-type="table-fn"}
  **No. of providers**                                          63,109                                          100.0 (---)                                         2,312              100.0 (---)         6,013   100.0 (---)                                         54,784   100.0 (---)
  1                                                             36,114                                          59.3 (58.6--60.0)[a](#T1FN1){ref-type="table-fn"}   1,201              53.2 (50.6--55.7)   3,379   57.3 (55.7--58.8)[a](#T1FN1){ref-type="table-fn"}   31,534   59.7 (58.9--60.5)[a](#T1FN1){ref-type="table-fn"}
  2 or 3                                                        17,345                                          26.4 (25.7--27.0)[b](#T1FN2){ref-type="table-fn"}   739                32.6 (30.3--35.1)   1,757   29.5 (28.1--31.0)[b](#T1FN2){ref-type="table-fn"}   14,849   25.8 (25.1--26.5)[b](#T1FN2){ref-type="table-fn"}
  ≥4                                                            9,650                                           14.3 (13.8--14.9)                                   372                14.2 (12.5--16.0)   877     13.2 (12.2--14.3)                                   8,401    14.5 (13.9--15.1)
  **No. of physician contacts in the past year**                62,668                                          100.0 (---)                                         2,283              100.0 (---)         5,975   100.0 (---)                                         54,410   100.0 (---)
  None                                                          8,356                                           15.2 (14.6--15.8)[a](#T1FN1){ref-type="table-fn"}   267                12.8 (11.1--14.8)   738     13.4 (12.3--14.6)                                   7,351    15.5 (14.8--16.1)[a](#T1FN1){ref-type="table-fn"}
  1                                                             17,801                                          30.0 (29.3--30.7)[a](#T1FN1){ref-type="table-fn"}   568                25.6 (23.3--27.9)   1,622   29.1 (27.6--30.6)[a](#T1FN1){ref-type="table-fn"}   15,611   30.3 (29.5--31.1)[a](#T1FN1){ref-type="table-fn"}
  2 or 3                                                        22,914                                          35.2 (34.5--35.9)                                   852                36.3 (33.9--38.8)   2,275   37.5 (36.0--39.1)                                   19,787   34.9 (34.1--35.7)
  ≥4                                                            13,597                                          19.6 (19.0--20.1)[b](#T1FN2){ref-type="table-fn"}   596                25.3 (23.1--27.6)   1,340   20.0 (18.8--21.3)[b](#T1FN2){ref-type="table-fn"}   11,661   19.3 (18.7--20.0)[b](#T1FN2){ref-type="table-fn"}
  **Type of facility where vaccinations were received**         62,872                                          100.0 (---)                                         2,301              100.0 (---)         5,990   100.0 (---)                                         54,581   100.0 (---)
  All private                                                   31,374                                          53.4 (52.7--54.2)[a](#T1FN1){ref-type="table-fn"}   810                36.0 (33.5--38.5)   2,804   47.6 (46.0--49.2)[a](#T1FN1){ref-type="table-fn"}   27,760   54.7 (53.9--55.5)[a](#T1FN1){ref-type="table-fn"}
  All public                                                    9,205                                           14.8 (14.3--15.4)[b](#T1FN2){ref-type="table-fn"}   570                26.1 (23.9--28.5)   1,060   17.3 (16.1--18.5)[b](#T1FN2){ref-type="table-fn"}   7,575    14.1 (13.6--14.8)[b](#T1FN2){ref-type="table-fn"}
  All hospital                                                  7,222                                           9.7 (9.3--10.1)[a](#T1FN1){ref-type="table-fn"}     187                8.2 (6.9--9.8)      565     9.5 (8.6--10.5)                                     6,470    9.8 (9.3--10.2)[a](#T1FN1){ref-type="table-fn"}
  Mixed[e](#T1FN5){ref-type="table-fn"}                         13,135                                          18.9 (18.3--19.4)[b](#T1FN2){ref-type="table-fn"}   677                27.1 (24.9--29.4)   1,401   22.9 (21.6--24.2)[b](#T1FN2){ref-type="table-fn"}   11,057   18.1 (17.5--18.8)[b](#T1FN2){ref-type="table-fn"}
  Other[f](#T1FN6){ref-type="table-fn"}                         1,936                                           3.2 (2.9--3.5)                                      57                 2.6 (1.9--3.5)      160     2.8 (2.3--3.3)                                      1,719    3.3 (3.0--3.6)
  **Metropolitan Statistical Area (MSA)**                       63,299                                          100.0 (---)                                         2,317              100.0 (---)         6,028   100.0 (---)                                         54,954   100.0 (---)
  Urban                                                         25,628                                          40.4 (39.7--41.1)[a](#T1FN1){ref-type="table-fn"}   572                27.8 (25.5--30.3)   2,388   37.6 (36.1--39.0)[a](#T1FN1){ref-type="table-fn"}   22,668   41.1 (40.3--41.9)[a](#T1FN1){ref-type="table-fn"}
  Suburban                                                      24,989                                          47.1 (46.3--47.8)[a](#T1FN1){ref-type="table-fn"}   796                34.7 (32.3--37.1)   2,345   44.6 (43.1--46.2)[a](#T1FN1){ref-type="table-fn"}   21,848   47.8 (47.0--48.6)[a](#T1FN1){ref-type="table-fn"}
  Rural                                                         12,682                                          12.6 (12.2--12.9)[b](#T1FN2){ref-type="table-fn"}   949                37.5 (35.1--40.0)   1,295   17.8 (16.7--19.0)[b](#T1FN2){ref-type="table-fn"}   10,438   11.1 (10.7--11.5)[b](#T1FN2){ref-type="table-fn"}

Abbreviations: CI, confidence interval; HPV, human papillomavirus; DRA, Delta Regional Authority.

*P* \< .05; value significantly higher than value for similar group in DRA counties; determined by multivariable logistic regression analysis.

*P* \< .05; value significantly lower than value for similar group in DRA counties; determined by χ^2^ test.

Insurance categories are mutually exclusive.

Includes Indian Health Service (IHS), Children's Health Insurance Programs (CHIP), and some private insurers.

Mixed indicates that a combination of facility types was listed (private, public, hospital, and STD/school/teen clinics) for the adolescent.

Includes military health care facilities; Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) clinics; and pharmacies.

Unadjusted HPV vaccination initiation coverage estimates among adolescents in the DRA region were significantly lower (54.3%) than in non-Delta states (61.4%) but similar to coverage in Delta areas outside the DRA region (56.2%) ([Table 2](#T2){ref-type="table"}). These findings persisted after adjusting for sociodemographic and health care--related variables. Despite the difference in coverage among the 3 areas, unadjusted results demonstrated that HPV vaccination initiation coverage followed a similar pattern in each geographic area. In all 3 geographic areas, HPV vaccination initiation coverage was significantly higher among girls, adolescents who were non-Hispanic white, adolescents whose mother had less than a high school education, adolescents whose mother was not currently married, adolescents who had a well-child visit at age 11 or 12, adolescents who had Medicaid (compared with those having private insurance), adolescents who had received a provider recommendation for HPV vaccination, and adolescents who resided in an urban area ([Table 2](#T2){ref-type="table"}). However, after adjusting for sociodemographic and health care characteristics, the factors that remained significantly associated with HPV vaccination initiation coverage varied by geographic area.

###### Unadjusted and Adjusted Logistic Regression Analysis for Vaccination Coverage Estimates (≥1 HPV Dose) Among Adolescents Aged 13--17 Years, by Geographic Area for Selected Sociodemographic Characteristics, National Immunization Survey-Teen, United States, 2015--2017

  Characteristic                                                  All Surveyed Adolescents in United States           Mississippi Delta States                            Non-Delta States                                                                                                                                                                                                                                                    
  --------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  **Overall**                                                     60.7 (60.0--61.4)[b](#T2FN2){ref-type="table-fn"}   ---                                                 54.3 (51.7--56.8)                                   Ref                                                 56.2 (54.6--57.8)                                   1.01 (.95--1.06)                                    61.4 (60.6--62.2)[b](#T2FN2){ref-type="table-fn"}   1.06 (1.01--1.11)[b](#T2FN2){ref-type="table-fn"}
  **Interview year**                                                                                                                                                                                                                                                                                                                                                                                                                          
  2015                                                            56.1 (54.9--57.4)[b](#T2FN2){ref-type="table-fn"}   0.91 (0.88--0.93)[b](#T2FN2){ref-type="table-fn"}   50.0 (45.8--54.3)[b](#T2FN2){ref-type="table-fn"}   0.96 (0.86--1.08)                                   51.1 (48.4--53.9)[b](#T2FN2){ref-type="table-fn"}   0.90 (0.84--0.97)[b](#T2FN2){ref-type="table-fn"}   56.9 (55.5--58.3)[b](#T2FN2){ref-type="table-fn"}   0.91 (0.88--0.94)[b](#T2FN2){ref-type="table-fn"}
  2016                                                            60.4 (59.2--61.6)[b](#T2FN2){ref-type="table-fn"}   0.95 (0.93--0.98)[b](#T2FN2){ref-type="table-fn"}   55.4 (50.9--59.8)                                   1.04 (0.93--1.17)                                   56.5 (53.6--59.2)[b](#T2FN2){ref-type="table-fn"}   0.97 (0.91--1.04)[b](#T2FN2){ref-type="table-fn"}   61.0 (59.7--62.4)[b](#T2FN2){ref-type="table-fn"}   0.95 (0.92--0.98)[b](#T2FN2){ref-type="table-fn"}
  2017                                                            65.5 (64.3--66.7)                                   Ref                                                 57.9 (53.2--62.4)                                   Ref                                                 61.0 (58.3--63.6)[b](#T2FN2){ref-type="table-fn"}   Ref                                                 66.3 (65.0--67.6)                                   Ref
  **Sex**                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Male                                                            56.1 (55.1--57.1)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.91--0.96)[b](#T2FN2){ref-type="table-fn"}   48.8 (45.3--52.4)[b](#T2FN2){ref-type="table-fn"}   0.91 (0.83--1.00)                                   51.5 (49.2--53.7)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.88--0.99)[b](#T2FN2){ref-type="table-fn"}   56.9 (55.8--58.0)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.91--0.96)[b](#T2FN2){ref-type="table-fn"}
  Female                                                          65.5 (64.5--66.5)                                   Ref                                                 60.2 (56.5--63.8)                                   Ref                                                 61.1 (58.9--63.3)                                   Ref                                                 66.1 (65.0--67.3)                                   Ref
  **Age of adolescent at interview, y**                                                                                                                                                                                                                                                                                                                                                                                                       
  13                                                              55.6 (54.0--57.2)[b](#T2FN2){ref-type="table-fn"}   0.86 (0.83--0.89)[b](#T2FN2){ref-type="table-fn"}   51.6 (46.1--57.1)                                   0.96 (0.83--1.11)                                   45.6 (42.1--49.1)[b](#T2FN2){ref-type="table-fn"}   0.78 (0.70--0.86)[b](#T2FN2){ref-type="table-fn"}   56.9 (55.1--58.7)[b](#T2FN2){ref-type="table-fn"}   0.86 (0.83--0.90)[b](#T2FN2){ref-type="table-fn"}
  14                                                              59.3 (57.7--60.9)[b](#T2FN2){ref-type="table-fn"}   0.89 (0.86--0.93)[b](#T2FN2){ref-type="table-fn"}   53.7 (47.7--59.5)                                   0.92 (0.79--1.07)                                   57.0 (53.4--60.6)                                   0.92 (0.84--1.00)                                   59.7 (57.9--61.5)[b](#T2FN2){ref-type="table-fn"}   0.89 (0.86--0.93)[b](#T2FN2){ref-type="table-fn"}
  15                                                              61.8 (60.2--63.4)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.91--0.98)[b](#T2FN2){ref-type="table-fn"}   57.8 (52.2--63.2)                                   1.06 (0.93--1.21)                                   57.4 (53.9--60.8)                                   0.95 (0.87--1.03)                                   62.4 (60.6--64.2)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.90--0.97)[b](#T2FN2){ref-type="table-fn"}
  16                                                              62.2 (60.7--63.7)[b](#T2FN2){ref-type="table-fn"}   0.95 (0.92--0.98)[b](#T2FN2){ref-type="table-fn"}   55.5 (49.9--61.1)                                   1.01 (0.88--1.16)                                   61.5 (58.1--64.8)                                   1.03 (0.95--1.12)                                   62.5 (60.8--64.2)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.90--0.97)[b](#T2FN2){ref-type="table-fn"}
  17                                                              64.6 (63.0--66.2)                                   Ref                                                 52.9 (46.9--58.9)                                   Ref                                                 59.3 (55.6--62.9)                                   Ref                                                 65.6 (63.9--67.4)                                   Ref
  **Adolescent's race/ethnicity**                                                                                                                                                                                                                                                                                                                                                                                                             
  Non-Hispanic white                                              55.3 (54.5--56.2)                                   Ref                                                 46.8 (43.4--50.2)                                   Ref                                                 50.7 (48.7--52.6)                                   Ref                                                 56.3 (55.3--57.2)                                   Ref
  Non-Hispanic black                                              65.3 (63.3--67.2)[b](#T2FN2){ref-type="table-fn"}   1.07 (1.03--1.12)[b](#T2FN2){ref-type="table-fn"}   60.8 (56.2--65.1)[b](#T2FN2){ref-type="table-fn"}   1.03 (0.91--1.15)                                   65.3 (60.9--69.4)[b](#T2FN2){ref-type="table-fn"}   1.15 (1.05--1.26)[b](#T2FN2){ref-type="table-fn"}   65.7 (63.4--68.0)[b](#T2FN2){ref-type="table-fn"}   1.07 (1.02--1.12)[b](#T2FN2){ref-type="table-fn"}
  Hispanic                                                        69.4 (67.5--71.1)[b](#T2FN2){ref-type="table-fn"}   1.15 (1.11--1.20)[b](#T2FN2){ref-type="table-fn"}   69.6 (60.2--77.6)[b](#T2FN2){ref-type="table-fn"}   1.21 (1.01--1.45)                                   70.4 (66.2--74.3)[b](#T2FN2){ref-type="table-fn"}   1.29 (1.18--1.40)[b](#T2FN2){ref-type="table-fn"}   69.3 (67.4--71.2)[b](#T2FN2){ref-type="table-fn"}   1.14 (1.10--1.19)[b](#T2FN2){ref-type="table-fn"}
  Other                                                           62.5 (60.3--64.7)[b](#T2FN2){ref-type="table-fn"}   1.10 (1.06--1.15)[b](#T2FN2){ref-type="table-fn"}   64.5 (54.9--73.0)[b](#T2FN2){ref-type="table-fn"}   1.12 (0.94--1.34)                                   59.6 (54.1--64.9)[b](#T2FN2){ref-type="table-fn"}   1.13 (1.02--1.25)[b](#T2FN2){ref-type="table-fn"}   62.8 (60.4--65.1)[b](#T2FN2){ref-type="table-fn"}   1.10 (1.05--1.14)[b](#T2FN2){ref-type="table-fn"}
  **Mother's education**                                                                                                                                                                                                                                                                                                                                                                                                                      
  \<High school graduate                                          71.8 (69.7--73.8)                                   Ref                                                 65.6 (59.0--71.6)                                   Ref                                                 64.9 (60.7--68.8)                                   Ref                                                 72.6 (70.3--74.8)                                   Ref
  High school graduate                                            61.1 (59.4--62.7)[b](#T2FN2){ref-type="table-fn"}   0.88 (0.84--0.92)[b](#T2FN2){ref-type="table-fn"}   54.2 (48.8--59.5)[b](#T2FN2){ref-type="table-fn"}   0.86 (0.74--1.00)                                   58.0 (54.4--61.6)[b](#T2FN2){ref-type="table-fn"}   0.97 (0.87--1.07)                                   61.7 (59.9--63.5)[b](#T2FN2){ref-type="table-fn"}   0.87 (0.83--0.92)[b](#T2FN2){ref-type="table-fn"}
  \>High school graduate, some college                            57.0 (55.5--58.4)[b](#T2FN2){ref-type="table-fn"}   0.82 (0.78--0.86)[b](#T2FN2){ref-type="table-fn"}   54.5 (49.9--59.1)[b](#T2FN2){ref-type="table-fn"}   0.80 (0.69--0.92)[b](#T2FN2){ref-type="table-fn"}   53.9 (50.9--56.9)[b](#T2FN2){ref-type="table-fn"}   0.86 (0.78--0.96)[b](#T2FN2){ref-type="table-fn"}   57.5 (55.8--59.1)[b](#T2FN2){ref-type="table-fn"}   0.82 (0.78--0.87)[b](#T2FN2){ref-type="table-fn"}
  College graduate                                                59.1 (58.0--60.1)[b](#T2FN2){ref-type="table-fn"}   0.87 (0.83--0.92)[b](#T2FN2){ref-type="table-fn"}   49.3 (45.0--53.7)[b](#T2FN2){ref-type="table-fn"}   0.86 (0.74--1.01)                                   54.3 (51.8--56.7)[b](#T2FN2){ref-type="table-fn"}   0.91 (0.81--1.01)                                   59.8 (58.7--61.0)[b](#T2FN2){ref-type="table-fn"}   0.87 (0.83--0.92)[b](#T2FN2){ref-type="table-fn"}
  **Mother's marital status**                                                                                                                                                                                                                                                                                                                                                                                                                 
  Married                                                         58.1 (57.3--59.0)                                   Ref                                                 46.1 (42.8--49.4)                                   Ref                                                 52.8 (50.8--54.7)                                   Ref                                                 59.0 (58.1--60.0)                                   Ref
  Divorced, widowed, or separated                                 61.8 (60.1--63.4)[b](#T2FN2){ref-type="table-fn"}   1.03 (1.00--1.07)[b](#T2FN2){ref-type="table-fn"}   62.2 (57.0--67.2)[b](#T2FN2){ref-type="table-fn"}   1.23 (1.10--1.38)[b](#T2FN2){ref-type="table-fn"}   58.8 (55.2--62.2)[b](#T2FN2){ref-type="table-fn"}   1.10 (1.02--1.18)[b](#T2FN2){ref-type="table-fn"}   62.1 (60.2--64.0)[b](#T2FN2){ref-type="table-fn"}   1.02 (0.98--1.06)
  Never married                                                   70.0 (67.6--72.3)[b](#T2FN2){ref-type="table-fn"}   1.09 (1.04--1.14)[b](#T2FN2){ref-type="table-fn"}   63.4 (56.0--70.3)[b](#T2FN2){ref-type="table-fn"}   1.17 (0.99--1.40)                                   67.8 (62.3--72.9)[b](#T2FN2){ref-type="table-fn"}   1.11 (0.99--1.24)                                   70.8 (68.1--73.4)[b](#T2FN2){ref-type="table-fn"}   1.09 (1.03--1.15)[b](#T2FN2){ref-type="table-fn"}
  **Mother's age, y**                                                                                                                                                                                                                                                                                                                                                                                                                         
  ≤34                                                             66.5 (64.1--68.9)                                   Ref                                                 56.5 (49.3--63.3)                                   Ref                                                 53.4 (48.2--58.5)                                   Ref                                                 68.8 (66.1--71.4)                                   Ref
  35--44                                                          60.8 (59.7--61.9)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.89--0.97)[b](#T2FN2){ref-type="table-fn"}   59.3 (55.6--62.8)                                   1.10 (0.94--1.29)                                   57.4 (55.0--59.7)                                   1.05 (0.94--1.17)                                   61.3 (60.0--62.5)[b](#T2FN2){ref-type="table-fn"}   0.91 (0.86--0.96)[b](#T2FN2){ref-type="table-fn"}
  ≥45                                                             59.5 (58.5--60.5)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.88--0.97)[b](#T2FN2){ref-type="table-fn"}   46.8 (42.7--50.8)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.78--1.12)                                   55.6 (53.2--57.9)                                   1.04 (0.93--1.17)                                   60.3 (59.2--61.3)[b](#T2FN2){ref-type="table-fn"}   0.91 (0.86--0.96)[b](#T2FN2){ref-type="table-fn"}
  **Adolescent had preventive care visit at age 11 or 12**                                                                                                                                                                                                                                                                                                                                                                                    
  Yes                                                             61.6 (60.9--62.3)[b](#T2FN2){ref-type="table-fn"}   1.08 (1.02--1.13)[b](#T2FN2){ref-type="table-fn"}   55.9 (53.1--58.6)[b](#T2FN2){ref-type="table-fn"}   1.12 (0.94--1.34)                                   57.4 (55.8--59.1)[b](#T2FN2){ref-type="table-fn"}   1.10 (0.97--1.24)                                   62.3 (61.4--63.1)[b](#T2FN2){ref-type="table-fn"}   1.07 (1.02--1.13)[b](#T2FN2){ref-type="table-fn"}
  No                                                              53.8 (51.2--56.3)                                   Ref                                                 42.3 (34.8--50.2)                                   Ref                                                 45.6 (40.1--51.2)                                   Ref                                                 55.2 (52.3--58.0)                                   Ref
  **Income-to-poverty ratio**                                                                                                                                                                                                                                                                                                                                                                                                                 
  \<133%                                                          67.8 (66.5--69.1)[b](#T2FN2){ref-type="table-fn"}   1.01 (0.96--1.06)                                   63.0 (58.9--66.9)[b](#T2FN2){ref-type="table-fn"}   0.99 (0.84--1.17)                                   63.4 (60.5--66.1)                                   1.01 (0.91--1.13)                                   68.5 (67.0--70.0)[b](#T2FN2){ref-type="table-fn"}   1.01 (0.96--1.06)
  133% to \<322%                                                  56.2 (54.8--57.5)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.89--0.96)[b](#T2FN2){ref-type="table-fn"}   48.0 (43.1--52.9)                                   0.84 (0.73--0.98)[b](#T2FN2){ref-type="table-fn"}   50.7 (47.7--53.7)[b](#T2FN2){ref-type="table-fn"}   0.88 (0.81--0.96)[b](#T2FN2){ref-type="table-fn"}   57.2 (55.6--58.7)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.90--0.97)[b](#T2FN2){ref-type="table-fn"}
  322% to \<503%                                                  55.0 (53.4--56.6)[b](#T2FN2){ref-type="table-fn"}   0.95 (0.92--0.98)[b](#T2FN2){ref-type="table-fn"}   46.3 (40.1--52.5)                                   0.94 (0.82--1.07)                                   49.4 (45.9--52.9)[b](#T2FN2){ref-type="table-fn"}   0.89 (0.82--0.97)[b](#T2FN2){ref-type="table-fn"}   55.8 (54.1--57.6)[b](#T2FN2){ref-type="table-fn"}   0.96 (0.92--0.99)[b](#T2FN2){ref-type="table-fn"}
  ≥503%                                                           60.8 (59.4--62.3)                                   Ref                                                 49.1 (43.2--55.0)                                   Ref                                                 59.4 (56.0--62.8)                                   Ref                                                 61.2 (59.7--62.7)                                   Ref
  **Health insurance coverage[c](#T2FN3){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                                                                                               
  Private only                                                    56.9 (56.0--57.8)                                   Ref                                                 44.1 (40.3--48.0)                                   Ref                                                 52.8 (50.7--55.0)                                   Ref                                                 57.7 (56.6--58.7)                                   Ref
  Any Medicaid                                                    67.8 (66.6--69.0)[b](#T2FN2){ref-type="table-fn"}   1.10 (1.06--1.14)[b](#T2FN2){ref-type="table-fn"}   62.9 (59.2--66.4)[b](#T2FN2){ref-type="table-fn"}   1.22 (1.06--1.42)[b](#T2FN2){ref-type="table-fn"}   62.3 (59.7--64.9)[b](#T2FN2){ref-type="table-fn"}   1.06 (0.98--1.16)                                   68.7 (67.3--70.1)[b](#T2FN2){ref-type="table-fn"}   1.10 (1.05--1.15)[b](#T2FN2){ref-type="table-fn"}
  Other[d](#T2FN4){ref-type="table-fn"}                           56.8 (54.3--59.3)                                   1.00 (0.95--1.05)                                   50.9 (41.2--60.5)                                   0.93 (0.73--1.19)                                   55.7 (49.1--62.2)                                   1.03 (0.90--1.18)                                   57.1 (54.3--59.8)                                   1.00 (0.95--1.05)
  Uninsured                                                       51.2 (47.4--55.0)[b](#T2FN2){ref-type="table-fn"}   0.94 (0.87--1.02)                                   44.5 (31.7--58.2)                                   1.16 (0.85--1.58)                                   41.9 (33.3--51.1)[b](#T2FN2){ref-type="table-fn"}   0.76 (0.60--0.97)[b](#T2FN2){ref-type="table-fn"}   52.3 (48.1--56.5)[b](#T2FN2){ref-type="table-fn"}   0.95 (0.87--1.03)
  **Provider recommended HPV vaccination**                                                                                                                                                                                                                                                                                                                                                                                                    
  Yes                                                             71.3 (70.4--72.1)[b](#T2FN2){ref-type="table-fn"}   1.95 (1.86--2.04)[b](#T2FN2){ref-type="table-fn"}   68.0 (64.7--71.1)[b](#T2FN2){ref-type="table-fn"}   2.07 (1.79--2.40)[b](#T2FN2){ref-type="table-fn"}   67.8 (65.9--69.6)[b](#T2FN2){ref-type="table-fn"}   2.02 (1.83--2.22)[b](#T2FN2){ref-type="table-fn"}   71.7 (70.8--72.6)[b](#T2FN2){ref-type="table-fn"}   1.94 (1.84--2.04)[b](#T2FN2){ref-type="table-fn"}
  No                                                              36.8 (35.3--38.3)                                   Ref                                                 32.2 (28.1--36.6)                                   Ref                                                 33.1 (30.3--36.1)                                   Ref                                                 37.5 (35.7--39.2)                                   Ref
  **No. of providers**                                                                                                                                                                                                                                                                                                                                                                                                                        
  1                                                               62.5 (61.5--63.4)                                   Ref                                                 55.8 (52.3--59.3)                                   Ref                                                 58.2 (56.1--60.3)                                   Ref                                                 63.1 (62.1--64.1)                                   Ref
  2 or 3                                                          59.2 (57.8--60.6)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.90--0.96)[b](#T2FN2){ref-type="table-fn"}   52.9 (48.4--57.4)                                   1.03 (0.93--1.15)                                   55.0 (52.0--57.9)                                   0.96 (0.89--1.03)                                   60.0 (58.4--61.6)[b](#T2FN2){ref-type="table-fn"}   0.92 (0.89--0.95)[b](#T2FN2){ref-type="table-fn"}
  ≥4                                                              56.7 (54.7--58.6)[b](#T2FN2){ref-type="table-fn"}   0.89 (0.85--0.93)[b](#T2FN2){ref-type="table-fn"}   52.0 (45.3--58.6)                                   1.00 (0.84--1.18)                                   51.0 (46.7--55.2)[b](#T2FN2){ref-type="table-fn"}   0.92 (0.83--1.01)                                   57.4 (55.2--59.6)[b](#T2FN2){ref-type="table-fn"}   0.89 (0.85--0.93)[b](#T2FN2){ref-type="table-fn"}
  **No. of physician contacts in the past year**                                                                                                                                                                                                                                                                                                                                                                                              
  None                                                            53.4 (51.3--55.5)                                   Ref                                                 53.1 (45.4--60.7)                                   Ref                                                 48.6 (44.0--53.2)                                   Ref                                                 53.9 (51.6--56.2)                                   Ref
  1                                                               59.2 (57.8--60.6)[b](#T2FN2){ref-type="table-fn"}   1.07 (1.02--1.11)[b](#T2FN2){ref-type="table-fn"}   49.5 (44.3--54.7)                                   0.86 (0.72--1.02)                                   54.8 (51.8--57.9)[b](#T2FN2){ref-type="table-fn"}   1.04 (0.94--1.15)                                   60.0 (58.4--61.5)[b](#T2FN2){ref-type="table-fn"}   1.07 (1.02--1.13)[b](#T2FN2){ref-type="table-fn"}
  2 or 3                                                          63.3 (62.2--64.5)[b](#T2FN2){ref-type="table-fn"}   1.12 (1.07--1.17)[b](#T2FN2){ref-type="table-fn"}   54.0 (49.8--58.1)                                   0.92 (0.79--1.08)                                   58.2 (55.6--60.7)[b](#T2FN2){ref-type="table-fn"}   1.07 (0.97--1.17)                                   64.3 (63.0--65.5)[b](#T2FN2){ref-type="table-fn"}   1.13 (1.08--1.18)[b](#T2FN2){ref-type="table-fn"}
  ≥4                                                              63.6 (62.1--65.0)[b](#T2FN2){ref-type="table-fn"}   1.12 (1.07--1.17)[b](#T2FN2){ref-type="table-fn"}   59.0 (53.9--63.9)                                   0.97 (0.82--1.14)                                   59.2 (55.8--62.5)[b](#T2FN2){ref-type="table-fn"}   1.10 (0.99--1.22)                                   64.3 (62.6--65.9)[b](#T2FN2){ref-type="table-fn"}   1.12 (1.07--1.18)[b](#T2FN2){ref-type="table-fn"}
  **Type of facility where vaccinations were obtained**                                                                                                                                                                                                                                                                                                                                                                                       
  All private                                                     60.7 (59.7--61.7)                                   Ref                                                 56.3 (52.0--60.5)                                   Ref                                                 57.5 (55.2--59.8)                                   Ref                                                 61.1 (60.0--62.2)                                   Ref
  All public                                                      60.7 (58.9--62.6)                                   1.00 (0.96--1.04)                                   52.7 (47.4--57.9)                                   0.92 (0.80--1.06)                                   54.3 (50.4--58.2)                                   0.97 (0.88--1.06)                                   62.1 (60.0--64.3)                                   1.01 (0.96--1.06)
  All hospital                                                    64.6 (62.6--66.6)[b](#T2FN2){ref-type="table-fn"}   1.03 (0.99--1.07)                                   61.9 (52.3--70.6)                                   1.00 (0.85--1.18)                                   59.4 (54.2--64.4)                                   0.97 (0.88--1.08)                                   65.3 (63.0--67.5)[b](#T2FN2){ref-type="table-fn"}   1.04 (1.00--1.09)
  Mixed[e](#T2FN5){ref-type="table-fn"}                           61.0 (59.4--62.6)                                   1.06 (1.02--1.10)[b](#T2FN2){ref-type="table-fn"}   51.3 (46.5--56.1)                                   0.94 (0.82--1.07)                                   55.9 (52.5--59.2)                                   1.02 (0.94--1.10)                                   62.2 (60.4--64.0)                                   1.07 (1.03--1.11)[b](#T2FN2){ref-type="table-fn"}
  Other[f](#T2FN6){ref-type="table-fn"}                           53.6 (49.0--58.1)[b](#T2FN2){ref-type="table-fn"}   0.92 (0.85--1.00)[b](#T2FN2){ref-type="table-fn"}   56.7 (41.1--71.1)                                   1.15 (0.93--1.44)                                   44.0 (34.5--53.8)[b](#T2FN2){ref-type="table-fn"}   0.79 (0.64--0.99)[b](#T2FN2){ref-type="table-fn"}   54.4 (49.4--59.4)[b](#T2FN2){ref-type="table-fn"}   0.93 (0.85--1.01)
  **Metropolitan Statistical Area (MSA)**                                                                                                                                                                                                                                                                                                                                                                                                     
  Urban                                                           66.1 (65.0--67.3)[b](#T2FN2){ref-type="table-fn"}   1.13 (1.10--1.17)[b](#T2FN2){ref-type="table-fn"}   61.7 (56.4--66.7)[b](#T2FN2){ref-type="table-fn"}   1.14 (1.00--1.29)[b](#T2FN2){ref-type="table-fn"}   63.5 (61.0--65.9)[b](#T2FN2){ref-type="table-fn"}   1.17 (1.07--1.28)[b](#T2FN2){ref-type="table-fn"}   66.5 (65.3--67.7)[b](#T2FN2){ref-type="table-fn"}   1.13 (1.09--1.18)[b](#T2FN2){ref-type="table-fn"}
  Suburban                                                        58.3 (57.2--59.3)[b](#T2FN2){ref-type="table-fn"}   1.05 (1.02--1.09)[b](#T2FN2){ref-type="table-fn"}   53.6 (49.3--57.8)                                   1.06 (0.95--1.19)                                   54.8 (52.3--57.3)[b](#T2FN2){ref-type="table-fn"}   1.11 (1.01--1.21)[b](#T2FN2){ref-type="table-fn"}   58.8 (57.6--59.9)[b](#T2FN2){ref-type="table-fn"}   1.05 (1.00--1.09)[b](#T2FN2){ref-type="table-fn"}
  Rural                                                           52.3 (50.8--53.8)                                   Ref                                                 49.5 (45.4--53.5)                                   Ref                                                 44.4 (40.9--48.0)                                   Ref                                                 54.1 (52.3--55.9)                                   Ref

Abbreviations: APR, adjusted prevalence ratio; CI, confidence interval; DRA, Delta Regional Authority; HPV, human papillomavirus; Ref, reference.

Percentages are weighted; estimates with 95% CI \>20 might not be reliable.

*P* \< .05 by *t* test for comparison with reference group.

Insurance categories are mutually exclusive.

Includes Indian Health Service (IHS), Children's Health Insurance Programs (CHIP), and some private insurers.

"Mixed" indicates that a combination of facility types was listed (private, public, hospital, and STD/school/teen clinics) for the adolescent and not just one type.

Includes military health care facilities, Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) clinics, and pharmacies.

In DRA areas, characteristics independently associated with higher rates of HPV vaccination initiation coverage (ie, APR \>1 and *P* value \<.05) among adolescents were having a mother who was divorced, widowed, or separated compared with a married mother, having Medicaid health insurance compared with having only private insurance, having received a provider recommendation for HPV vaccination compared with no provider recommendation, and residing in urban areas compared with rural areas ([Table 2](#T2){ref-type="table"}). Lower HPV vaccination initiation coverage (ie, 0 \< APR \< 1 and *P* value \<.05) was found among adolescents whose mothers were high school graduates or had some college compared with mothers having less than a high school education, and those with a household IPR of 133% to less than 322% compared with those having a household IPR of 503% or more.

In the Delta region outside the DRA, factors associated with higher HPV vaccination initiation coverage were identification as non-Hispanic black, Hispanic, or other race/ethnicity compared with adolescents identified as non-Hispanic white; having a mother who was divorced, widowed, or separated, compared with a married mother; receipt of a provider recommendation for HPV vaccination compared with no provider recommendation; and residing in urban or suburban areas compared with rural areas ([Table 2](#T2){ref-type="table"}). Factors associated with lower HPV vaccination initiation coverage were being male; being aged 13 compared with aged 17; having a mother who was a high school graduate or had some college, compared with a mother having less than a high school education; having a household IPR from 133% to less than 503% compared with those having a household IPR of 503% or more; being uninsured compared with having only private insurance; and having received all vaccinations at an "other" facility compared with an all private facility.

In non-Delta states, factors associated with higher HPV vaccination initiation coverage among adolescents were identification as non-Hispanic black, Hispanic, or other compared with non-Hispanic white; having a mother who had never married compared with a married mother; having received a preventive care visit at age 11 or 12 compared with no visit; having Medicaid health insurance compared with only private insurance; having received a provider recommendation for HPV vaccination compared with no provider recommendation; having had at least 1 physician contact in the past year compared with no physician contact; having vaccinations in a mix of facility types compared with solely in private facilities; and residing in rural areas compared with residing in urban or suburban areas ([Table 2](#T2){ref-type="table"}).

Outside the Delta, factors associated with lower HPV vaccination initiation coverage were being male compared with female; being aged 13 to 16 compared with 17; having a mother who was a high school graduate compared with a mother with less than a high school education; having a mother aged 35 years or more compared with 34 years or less; having a household IPR of 133% to less than 503% compared with a household IPR of 503% or more; and having 2 or more vaccination providers compared with only 1 ([Table 2](#T2){ref-type="table"}).

In the DRA, among adolescents without any HPV vaccinations, 49.8% of parents reported a very likely or somewhat likely intent for their adolescent to receive the HPV vaccine in the next 12 months ([Table 3](#T3){ref-type="table"}). Among parents who did not intend to get their adolescent vaccinated (ie, those who responded not too likely, not likely at all, and not sure or don't know), the most common reasons for not intending to get the HPV vaccine were that vaccination is not necessary, not having received a recommendation for HPV vaccine from the provider, concerns about vaccine safety or side effects, lack of knowledge about the vaccine, and believing that their adolescents were not sexually active ([Table 3](#T3){ref-type="table"}). These results were not significantly different from findings in Delta areas outside the DRA or the non-Delta states.

###### Survey Responses Among Parents Whose Adolescent Child Had Not Yet Received HPV Vaccination, National Immunization Survey-Teen, United States, 2015--2017[a](#T3FN1){ref-type="table-fn"}

  Questions and Responses                                                                                                                                                     All Surveyed Teens in the United States   Mississippi Delta States   Non-Delta States    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- -------------------------- ------------------- -------------------
  **No. of parents who answered question, "How likely is it that \[TEEN\] will receive HPV shots in the next 12 months?"**                                                    40,929                                    1,633                      4,156               35,140
  **Responses**                                                                                                                                                                                                                                                        
  Very likely                                                                                                                                                                 28.9 (28.1--29.8)                         28.2 (25.5--31.1)          28.6 (26.9--30.4)   29.0 (28.1--30.0)
  Somewhat likely                                                                                                                                                             24.1 (23.3--24.9)                         21.6 (19.2--24.2)          23.6 (22.0--25.3)   24.2 (23.4--25.2)
  Not too likely                                                                                                                                                              16.8 (16.1--17.4)                         18.2 (16.0--20.7)          17.3 (15.8--18.8)   16.6 (15.9--17.4)
  Not likely at all                                                                                                                                                           26.7 (25.9--27.5)                         28.5 (25.9--31.3)          26.9 (25.2--28.6)   26.6 (25.7--27.5)
  Not sure or don\'t know                                                                                                                                                     3.5 (3.2--3.9)                            3.4 (2.4--4.7)             3.7 (3.0--4.5)      3.5 (3.2--3.9)
  **No. of parents who answered open-ended question, "What is the main reason \[TEEN\] will not receive HPV shots in the next 12 months?"[b](#T3FN2){ref-type="table-fn"}**   19,263                                    842                        2,023               16,398
  **Responses**                                                                                                                                                                                                                                                        
  Not needed or not necessary                                                                                                                                                 20.6 (19.4--21.9)                         20.8 (16.9--25.3)          19.6 (17.1--22.5)   20.8 (19.4--22.2)
  Safety concern or side effects                                                                                                                                              17.3 (16.2--18.3)                         15.4 (12.0--19.7)          16.4 (14.1--19.0)   17.4 (16.3--18.6)
  Not recommended                                                                                                                                                             13.1 (12.0--14.3)                         15.5 (11.9--20.0)          12.7 (10.6--15.2)   13.0 (11.8--14.4)
  Lack of knowledge                                                                                                                                                           10.9 (10.0--12.0)                         11.9 (8.9--15.6)           12.6 (10.4--15.1)   10.7 (9.6--11.8)
  Teen not sexually active                                                                                                                                                    10.3 (9.3--11.4)                          9.9 (7.3--13.3)            8.4 (6.8--10.4)     10.6 (9.5--11.8)

Abbreviations: DRA, Delta Regional Authority; HPV, human papillomavirus.

All values are weighted percentages (95% confidence intervals).

Responses are from parents and guardians who responded, "not too likely," "not likely at all," or "not sure or don't know" when asked how likely it was that the teen would receive an HPV vaccination in the next year.

Discussion
==========

The DRA is a subset of the most distressed counties and parishes in 8 states of the southeastern United States. Overall, HPV vaccination coverage inside the DRA region was similar to that in Delta areas outside the DRA but significantly lower than in non-Delta states. Although vaccination coverage was lower in the DRA region, the pattern of coverage was similar to the other 2 geographic areas; however, factors that remained significantly associated with coverage differed after adjusting for demographic characteristics, health insurance, and access to care variables. In the Delta states, factors associated with vaccination coverage included mother's marital status, mother's education level, poverty level, any Medicaid health insurance, residence in an urban area, and receiving a provider recommendation for HPV vaccination.

Among adolescents living in the DRA region, HPV vaccination initiation coverage was 19 percentage points higher for those with any Medicaid health insurance, compared with adolescents having private insurance coverage. The higher coverage might likely be because of the availability of vaccines through the VFC (Vaccines for Children) program in the United States ([@R21]), which provides vaccines at no cost to eligible children (ie, those without health insurance, who are Medicaid eligible, of American Indian or Alaska Native descent, or whose insurance does not cover the cost of vaccination). Although uninsured children can receive vaccines through the VFC program, vaccination coverage in the DRA region was low (44.5%) but similar to children with private insurance (44.1%). Additional efforts are needed to promote the use of the VFC program among those who are insured. Furthermore, although uninsured children face additional challenges beyond cost to receiving vaccines, understanding challenges to HPV vaccination for privately insured children is also needed.

Although provider recommendation for vaccination was associated with HPV vaccination initiation in all 3 geographic areas, children inside the DRA region were less likely to have received a provider recommendation for HPV vaccination than children outside the DRA region. Previous research has indicated that both the source and manner of recommendation influence parental receptiveness to HPV vaccination ([@R22],[@R23]); physicians are a trusted source of vaccination information and could be a crucial influence for increasing HPV vaccination in the DRA region and elsewhere. An announcement that includes a statement that assumes parents are ready to vaccinate results in higher vaccination coverage ([@R22]). CDC has developed resources incorporating these communication principles to demonstrate how to give an effective recommendation ([@R24]) that might be helpful for clinicians inside the DRA region and elsewhere. Among unvaccinated adolescents, the most common reason their parents did not intend to vaccinate them with the HPV vaccine was the belief that the vaccine was not necessary because their child was unlikely to have initiated sexual activity. This was a prevalent reason across all 3 geographic areas. Recent research has tested and identified effective messages to address these questions and concerns from parents ([@R24]). Messages emphasizing cancer prevention were more effective in increasing confidence to vaccinate among parents, whereas messages emphasizing urgency to vaccinate were counterproductive. Effective communication messages to providers are needed to improve their confidence and ability to discuss HPV vaccination with patients. To reach parents and adolescents with limited access to health care providers, engaging partners serving these populations (eg, the Special Supplemental Nutrition Program for Women, Infants, and Children \[WIC\]) might also be helpful.

Although a higher proportion of adolescents with 2 or 3 providers lived in the DRA region, compared with the other 2 geographic areas, vaccination coverage was not associated with the number of providers among adolescents in the DRA region. Those who have several health care providers might have their medical histories dispersed to multiple providers, and follow-up might be difficult or unlikely. Record scattering, shown to affect vaccination coverage for young children, might also contribute to lower HPV vaccination coverage ([@R25]). Encouraging providers to report vaccines they administer to their state immunization information system could help consolidate vaccination records and facilitate timely vaccination decisions during health care encounters.

Thirty-six percent of adolescents in the DRA region received all of their vaccinations at private facilities. Receipt of all vaccinations from private facilities was more common in the other 2 geographic areas. Additional research is needed to determine if this finding results from fewer private facilities operating in the DRA or a reduced likelihood among private facilities in the DRA region to stock and administer HPV vaccines.

This study has several strengths. First, NIS-Teen includes provider-reported vaccination data, which are more reliable than parental recall or vaccination shot cards. Second, multiple years of data were combined to increase sample size and study power to allow detailed analysis of this underserved geographic area. Third, although NIS-Teen was previously limited to households with landline telephones, this data set included cell phone sampling frames as well, which was instrumental in increasing how the data represented the target population.

Our study also had limitations. First, incomplete provider vaccination records and lack of data on community- or county-level factors that might influence HPV vaccination could have limited the scope of this study. Second, after weighting adjustments to mitigate bias from incomplete data in the sample frame and nonresponses, some bias may remain ([@R16]). Third, provider recommendation is also subject to recall bias. Finally, some estimates may be unreliable because of the small sample size. Despite these limitations, we believe our findings can raise awareness among providers and policy makers in the DRA region regarding disparities in HPV vaccination coverage, the need for strategies to increase HPV vaccination, and the target populations to consider for enhanced efforts.

Although factors related to HPV vaccine initiation are similar in the 3 areas studied, overall vaccination levels are lower in the Delta (both inside and outside the DRA region). Lower vaccination levels are likely correlated with the unique sociodemographic and health care characteristics of the areas, which are likely also responsible for disparities in HPV vaccination initiation across the 3 geographic areas. In the DRA region, assisting providers in effectively recommending HPV vaccination could be a primary strategy to increase coverage, as recommendations were closely associated with HPV vaccine initiation. Existing resources to help communicate HPV vaccine recommendations might need to be evaluated to ensure cultural appropriateness. To help identify strategies to increase HPV vaccination, additional research is needed to understand the barriers to vaccination in the Delta region, especially differences between uninsured and privately insured adolescents.
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